---
layout: default
title: Naftifine
description: "Naftifine 的老藥新用潛力分析。最高證據等級 L1，包含 8 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 高證據等級 (L1-L2)
nav_order: 109
evidence_level: L3
indication_count: 8
---

# Naftifine

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L1</strong> | 預測適應症: <strong>8</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Naftifine：從 皮膚黴菌病 到 皮膚念珠菌病

## 一句話總結

<p class="key-answer" data-question="Naftifine 可以用於治療什麼新適應症？">
Naftifine（萘替芬）是一種烯丙胺類局部抗黴菌藥，用於治療皮膚黴菌感染。TxGNN 模型預測它對**皮膚念珠菌病 (cutaneous candidiasis)** 和**花斑癬 (pityriasis versicolor)** 有治療效果，這些預測與其已核准適應症高度一致，有充分文獻支持。
</p>


## 快速總覽

| 項目 | 內容 |
|------|------|
| 原適應症 | 皮膚黴菌病、表皮念珠菌病、甲黴菌病、花斑癬 |
| 預測新適應症 | dermatophytosis of groin and perianal area、tinea pedis、tinea corporis、cutaneous candidiasis、Majocchi granuloma、ectothrix infectious disease、pityriasis versicolor、endothrix infectious disease |
| TxGNN 預測分數 | 99.84% (皮膚念珠菌病), 99.68% (花斑癬) |
| 證據等級 | L1 |
| 台灣上市 | 已上市 |
| 許可證數 | 多張 |
| 建議決策 | Validate |




## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. cutaneous candidiasis</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.84%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p><p class="key-answer" data-question="這個藥物的作用機轉是什麼？"></p>
<p>Naftifine 通過抑制角鯊烯環氧化酶（squalene epoxidase），阻斷麥角固醇合成，破壞真菌細胞膜完整性。</p>
<p></p></p>

<p><div class="key-takeaway"></p>
<p>此預測基於藥物的作用機轉，與現有臨床證據方向一致。</p>

<h3>臨床試驗</h3>

<p>雖無專門的 RCT 登記，但多項開放性研究已證實療效。</p>

<h3>相關文獻</h3>

<p><strong>皮膚念珠菌病：</strong></p>

<table>
<thead>
<tr>
<th>PMID</th>
<th>年份</th>
<th>類型</th>
<th>主要發現</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/3048914/">3048914</a></td>
<td>1988</td>
<td>RCT</td>
<td>雙盲試驗：77% 的 naftifine 治療患者達成真菌學治癒，對照組僅 3%</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/1723367/">1723367</a></td>
<td>1991</td>
<td>Review</td>
<td>綜述確認 naftifine 對皮膚念珠菌病有效</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/18346400/">18346400</a></td>
<td>2008</td>
<td>Review</td>
<td>確認 naftifine 對念珠菌和曲霉菌有效</td>
</tr>
</tbody>
</table>

<p><strong>花斑癬：</strong></p>

<table>
<thead>
<tr>
<th>PMID</th>
<th>年份</th>
<th>類型</th>
<th>主要發現</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/3531847/">3531847</a></td>
<td>1986</td>
<td>Clinical Trial</td>
<td>Naftifine 1% 溶液治療花斑癬的療效研究</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/22165042/">22165042</a></td>
<td>2011</td>
<td>Open-label Study</td>
<td>Naftifine 1% 凝膠每日兩次治療花斑癬 2 週，8 週時 50% 達真菌學陰性</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/8370053/">8370053</a></td>
<td>1993</td>
<td>Laboratory/Clinical</td>
<td>確認 naftifine 對皮膚真菌病和花斑癬的療效</td>
</tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. Majocchi granuloma</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.69%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（1 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23278484/" target="_blank">23278484</a></td><td>2013</td><td>Article</td><td>Pediatric dermatolog</td><td>Impetigo-like tinea faciei around the nostrils caused by Art...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. ectothrix infectious disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.69%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. pityriasis versicolor</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.68%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（8 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10439936/" target="_blank">10439936</a></td><td>1999</td><td>Article</td><td>Drugs</td><td>Terbinafine. An update of its use in superficial mycoses.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18840006/" target="_blank">18840006</a></td><td>2008</td><td>Article</td><td>Drugs</td><td>Topical fenticonazole in dermatology and gynaecology: curren...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22165042/" target="_blank">22165042</a></td><td>2011</td><td>Article</td><td>Skinmed</td><td>An open-label study of naftifine hydrochloride 1% gel in the...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3531847/" target="_blank">3531847</a></td><td>1986</td><td>Article</td><td>Mykosen</td><td>Naftifine solution (1%) in the treatment of pityriasis versi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24196340/" target="_blank">24196340</a></td><td>2013</td><td>Article</td><td>Journal of drugs in </td><td>Optimizing topical antifungal therapy for superficial cutane...</td></tr>
</tbody>
</table>
<p><em>...及其他 3 篇文獻</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. endothrix infectious disease</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.65%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（1 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02658292" target="_blank">NCT02658292</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>A Double-Blind, Randomized, Vehicle-Control, Multicenter Study to Evaluate the E...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. dermatophytosis of scalp or beard</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.65%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34934294/" target="_blank">34934294</a></td><td>2021</td><td>Article</td><td>International journa</td><td>Beard Reconstruction.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34984089/" target="_blank">34984089</a></td><td>2021</td><td>Article</td><td>Indian journal of pl</td><td>Beard and Moustache Reconstruction.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37510908/" target="_blank">37510908</a></td><td>2023</td><td>Article</td><td>Journal of clinical </td><td>Beard Alopecia: An Updated and Comprehensive Review of Etiol...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38106958/" target="_blank">38106958</a></td><td>2023</td><td>Article</td><td>International journa</td><td>Stress, a Brief Update.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38936998/" target="_blank">38936998</a></td><td>2024</td><td>Article</td><td>Facial plastic surge</td><td>Facial Hair in Hair Restoration Surgery: Beard Transplantati...</td></tr>
</tbody>
</table>
<p><em>...及其他 15 篇文獻</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. superficial mycosis</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.63%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37355825/" target="_blank">37355825</a></td><td>2023</td><td>Article</td><td>The Journal of the A</td><td>Naftifine: A Topical Allylamine for Superficial Dermatophyto...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18346400/" target="_blank">18346400</a></td><td>2008</td><td>Article</td><td>Journal of cutaneous</td><td>Naftifine: a review.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/1723367/" target="_blank">1723367</a></td><td>1991</td><td>Article</td><td>Drugs</td><td>Naftifine. A review of its antimicrobial activity and therap...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25502847/" target="_blank">25502847</a></td><td>2015</td><td>Article</td><td>Mycopathologia</td><td>Generalized superficial mycosis caused by Trichophyton raubi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33517791/" target="_blank">33517791</a></td><td>2021</td><td>Article</td><td>Drug delivery</td><td>Development, optimization and characterization of nanoemulsi...</td></tr>
</tbody>
</table>
<p><em>...及其他 15 篇文獻</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. tinea profunda</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.57%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（1 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23278484/" target="_blank">23278484</a></td><td>2013</td><td>Article</td><td>Pediatric dermatolog</td><td>Impetigo-like tinea faciei around the nostrils caused by Art...</td></tr>
</tbody>
</table>

</div>
</details>


## 台灣上市資訊

| 許可證號 | 品名 | 劑型 | 核准適應症 |
|---------|------|------|-----------|
| 多張許可證 | 鹽酸萘替芬 | 乳膏/溶液 | 皮膚真菌病、表皮念珠菌病、甲黴菌病、花斑癬 |

## 安全性考量

**常見副作用：**
- 局部灼熱感（6.8%）
- 局部刺激
- 皮膚乾燥
- 紅斑

**禁忌症：**
- 對 naftifine 或其他烯丙胺類藥物過敏

**使用注意：**
- 僅供外用
- 避免接觸眼睛和黏膜
- 如出現明顯刺激應停藥

## 結論與下一步

**決策：Validate**

**理由：**
TxGNN 預測的「皮膚念珠菌病」和「花斑癬」實際上已是 naftifine 在台灣的核准適應症（「表皮念珠菌病」和「花斑癬」）。文獻提供了充分的療效證據。此預測更多是對現有適應症的確認，而非新發現。

**若要推進需要：**
- 此藥物已被核准用於預測適應症
- 無需額外驗證研究
- 可直接依據仿單使用


---

## 相關藥物報告

- [Ipratropium]({{ "/drugs/ipratropium/" | relative_url }}) - 證據等級 L1
- [Temozolomide]({{ "/drugs/temozolomide/" | relative_url }}) - 證據等級 L1
- [Anastrozole]({{ "/drugs/anastrozole/" | relative_url }}) - 證據等級 L1
- [Icatibant]({{ "/drugs/icatibant/" | relative_url }}) - 證據等級 L1
- [Docetaxel]({{ "/drugs/docetaxel/" | relative_url }}) - 證據等級 L1

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Naftifine老藥新用驗證報告. https://twtxgnn.yao.care/drugs/naftifine/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_naftifine,
  title = {Naftifine老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/naftifine/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
